LENZ Therapeutics (LENZ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 19. Analyst Marc Goodman from Leerink Partners reiterated a Buy rating on the stock and has a $36.00 price target.
Marc Goodman has given his Buy rating due to a combination of factors that indicate a promising future for LENZ Therapeutics. The company’s recent financial results and business updates have reinforced his positive outlook. The presbyopia market is seen as a significant opportunity, and LENZ is well-positioned to capitalize on it.
The upcoming Commercial Day on April 15 is expected to provide more insights into their launch plans, with a product launch anticipated by the fourth quarter of 2025. The company has a strong cash position, which is believed to be sufficient to support operations until they achieve positive cash flow post-launch. Additionally, regulatory and manufacturing preparations are on track, and a significant portion of eye care professionals are expected to prescribe their product once approved.
According to TipRanks, Goodman is a 4-star analyst with an average return of 4.6% and a 45.42% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Evolus, and Stoke Therapeutics.
In another report released yesterday, Citi also reiterated a Buy rating on the stock with a $47.00 price target.